drugset / Trial / NCT06039254

Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function

NCT06039254

Phase 1 Unknown 27 enrolled Shandong Suncadia Medicine Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a multicenter, non-randomized, open-label, parallel-controlled study. The main objective is to evaluate the safety and pharmacokinetics of HRS-1780 in subjects with mild and moderate renal impairment versus healthy subjects, and to provide a basis for dose selection of HRS-1780 in patients with chronic kidney disease.

Timeline

Start
2023-09
Primary completion
2023-11-30
Completion
2023-12-08

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS-1780 Small molecule